Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2020)

Monopar Therapeutics' Cash from Operations history spans 4 years, with the latest figure at 1240696.0 for Q4 2020.

  • For Q4 2020, Cash from Operations fell 85.54% year-over-year to 1240696.0; the TTM value through Dec 2020 reached 4662274.0, down 54.5%, while the annual FY2024 figure was 6404139.0, 18.5% up from the prior year.
  • Cash from Operations for Q4 2020 was 1240696.0 at Monopar Therapeutics, up from 1300534.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 305128.0 in Q2 2017 and bottomed at 1300534.0 in Q3 2020.
  • The 4-year median for Cash from Operations is 780856.0 (2018), against an average of 811744.31.
  • The largest YoY upside for Cash from Operations was 49.82% in 2018 against a maximum downside of 159.67% in 2018.
  • A 4-year view of Cash from Operations shows it stood at 816021.0 in 2017, then surged by 36.37% to 519212.0 in 2018, then decreased by 28.79% to 668705.0 in 2019, then crashed by 85.54% to 1240696.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Cash from Operations are 1240696.0 (Q4 2020), 1300534.0 (Q3 2020), and 995474.0 (Q2 2020).